---
provider: openai
model: gpt-5
drug: Aspirin
disease: Myocardial Infarction
query: 'Research the mechanism by which Aspirin affects Myocardial Infarction.


  Produce a markdown response with EXACTLY this structure:


  ## Proposed mechanism summary

  2–3 paragraphs describing the mechanistic pathway from Aspirin to its effect

  on Myocardial Infarction, with inline (PMID:XXXX) citations.


  ## Candidate PMIDs

  Bulleted list, 5–15 PMIDs ordered by relevance:

  - PMID:XXXXXXXX — One-sentence relevance note.

  - ...


  Only include PMIDs you verified exist via web search.


  ## Mechanism graph proposal (advisory)

  Drug → intermediate1 → intermediate2 → ... → Disease


  Each arrow labeled with a Biolink-style predicate (e.g., "decreases activity

  of", "positively regulates", "contributes to"). This topology is advisory —

  the curation agent will validate it.


  Output ONLY the markdown body. No preamble or closing remarks.

  '
generated_at: '2026-06-02T20:22:23+00:00'
ttl_days: 30
candidate_pmids:
- PMID:2108169
- PMID:413839
- PMID:7045161
- PMID:6436696
- PMID:2899772
- PMID:2664509
- PMID:11786451
- PMID:6135989
- PMID:6411052
- PMID:1159076
- PMID:105363
- PMID:26859324
notes: input_tokens=41011, output_tokens=5656
---

## Proposed mechanism summary
Aspirin (acetylsalicylic acid) irreversibly acetylates the active-site serine of platelet cyclooxygenase‑1 (COX‑1; Ser530), inactivating the enzyme and blocking conversion of arachidonic acid to the pro‑aggregatory eicosanoid thromboxane A2 (TXA2). Because platelets are anucleate and cannot resynthesize COX‑1, a single exposure produces sustained suppression of TXA2 for the platelet lifespan, thereby reducing platelet activation and aggregation (PMID:2108169; PMID:413839). At low daily doses, aspirin shows functional selectivity for platelet TXA2 over endothelial prostacyclin due to presystemic (portal) acetylation of circulating platelets and rapid endothelial COX resynthesis, yielding near‑complete inhibition of platelet TXA2 with relatively preserved prostacyclin activity (PMID:7045161; PMID:6436696).

By diminishing TXA2‑mediated platelet aggregation, aspirin decreases formation of platelet‑rich coronary thrombi on ruptured atherosclerotic plaques, thereby lowering the risk and severity of occlusive events that precipitate myocardial infarction. This mechanistic pathway translates into clinical benefit: randomized trials show early aspirin in suspected acute MI reduces mortality, and low‑dose aspirin prevents first and recurrent nonfatal MI in appropriate populations; broad meta‑analyses across high‑risk patients confirm reductions in nonfatal MI and serious vascular events. Concomitant nonselective NSAIDs (e.g., ibuprofen) can transiently block aspirin’s access to platelet COX‑1 and blunt its antiplatelet effect, underscoring the centrality of irreversible COX‑1 acetylation to benefit (PMID:2899772; PMID:2664509; PMID:11786451; PMID:6135989; PMID:6411052).

## Candidate PMIDs
- PMID:2899772 — ISIS‑2: randomized trial showing aspirin reduces mortality in suspected acute MI, establishing clinical efficacy tied to antithrombotic mechanism.
- PMID:7045161 — JCI study demonstrating dose‑dependent, selective, cumulative inhibition of platelet TXA2 by low‑dose aspirin in humans.
- PMID:413839 — Classic human study showing oral aspirin irreversibly inhibits platelet prostaglandin synthetase (COX‑1), reducing platelet function.
- PMID:6436696 — NEJM pharmacokinetic/pharmacodynamic study explaining presystemic platelet COX‑1 acetylation that underlies low‑dose selectivity.
- PMID:2108169 — Molecular work identifying Ser530 acetylation of prostaglandin endoperoxide synthase (COX‑1) as the basis for irreversible inhibition.
- PMID:2664509 — Physicians’ Health Study final aspirin report showing primary prevention of first MI with alternate‑day low‑dose aspirin.
- PMID:11786451 — Antithrombotic Trialists’ Collaboration meta‑analysis confirming antiplatelet therapy (especially low‑dose aspirin) reduces nonfatal MI and serious vascular events in high‑risk patients.
- PMID:6135989 — VA Cooperative randomized trial in unstable angina showing aspirin lowers MI and death, linking platelet inhibition to coronary outcomes.
- PMID:6411052 — NEJM study demonstrating ibuprofen blocks aspirin’s irreversible platelet COX‑1 inhibition, highlighting the key mechanistic step.
- PMID:1159076 — Early platelet biochemistry showing aspirin acetylates a platelet particulate protein consistent with COX involvement.
- PMID:105363 — Differential sensitivity of vascular vs platelet COX to aspirin acetylation, supporting relative sparing of endothelial prostacyclin at low dose.
- PMID:26859324 — Structural characterization of aspirin‑acetylated COX‑2 including Ser530 context; corroborates covalent acetylation mechanism relevant to COX isozymes.

## Mechanism graph proposal (advisory)
Aspirin →(decreases activity of)→ Platelet COX‑1 (PTGS1) →(decreases synthesis of)→ Thromboxane A2 (TXA2) →(decreases activation/aggregation of)→ Platelets →(decreases formation of)→ Coronary platelet‑rich thrombus →(contributes to decreased risk of)→ Myocardial infarction
